Antiretroviral Boosting Agent Cobicistat Increases the Pharmacokinetic Exposure and Anticoagulant Effect of Dabigatran in HIV-Negative Healthy Volunteers.

Lori A Gordon Parag Kumar Kristina M Brooks Anela Kellogg Maryellen McManus Raul M Alfaro Khanh Nghiem Jomy M George Jay Lozier Scott R Penzak Colleen Hadigan

Circulation

From Clinical Pharmacokinetics Research Unit, Clinical Center Pharmacy Department, (L.A.G., R.K., K.M.B., R.M.A., J.M.G., S.R.P.), Clinical Research Center, Clinical Center Department of Laboratory Medicine (K.N., J.L.), National Institute of Allergy and Infectious Diseases (C.H.), National Institutes of Health, Bethesda, MD; Xavier University of Louisiana, College of Pharmacy, New Orleans (L.A.G.); Leidos Biomedical Research, Inc, Frederick, MD (A.K.); Parker Tide Corporation, Washington, DC (M.M.); and University of North Texas System College of Pharmacy, Department of Pharmacotherapy, Fort Worth (S.R.P.).

Published: December 2016

Download full-text PDF	Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5145004	PMC
http://dx.doi.org/10.1161/CIRCULATIONAHA.116.025257	DOI Listing

Publication Analysis

Top Keywords

antiretroviral boosting

boosting agent

agent cobicistat

cobicistat increases

increases pharmacokinetic

pharmacokinetic exposure

exposure anticoagulant

anticoagulant dabigatran

dabigatran hiv-negative

hiv-negative healthy

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!